币界网报道：Synaptogenix, a biopharmaceutical company, has announced a strategic investment in Bittensor (TAO) tokens as part of its treasury management strategy. The firm aims to diversify its holdings by allocating a portion of its cash reserves into the decentralized AI-focused blockchain project. Synaptogenix CEO Alan Tuchman highlighted the move as a forward-looking approach to leverage emerging technologies, citing Bittensor’s potential to revolutionize machine learning through decentralized networks. The investment aligns with the company’s broader interest in AI-driven innovations, complementing its core focus on neurodegenerative disease treatments. Bittensor’s TAO token, which powers its open-source protocol for decentralized AI development, has gained traction among institutional and retail investors. The announcement follows growing corporate interest in blockchain-based AI solutions, with companies exploring decentralized alternatives to traditional cloud-based models. Synaptogenix did not disclose the exact amount invested but emphasized its commitment to long-term growth through strategic crypto holdings. The decision reflects a broader trend of firms diversifying treasuries into digital assets amid increasing institutional adoption of blockchain technology.